GlassScriptPhysician profile
Olayinka O Toby
NPI 1740825413
$1,824.86
in general payments reported to CMS, 2019-2025
10 companies · $300 in 2025
The $300 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $261 · 2022: $278 · 2023: $681 · 2024: $305 · 2025: $300.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,286.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,285.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $787.69 | 2022-2025 | Ingrezza |
| Abbvie INC. | $448.41 | 2021-2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $228.28 | 2021-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $156.41 | 2024-2025 | Austedo Xr, Austedo Xr |
| Orexo US, INC. | $84.88 | 2021-2022 | |
| Indivior INC. | $55.43 | 2022-2023 | Perseris |
| Janssen Pharmaceuticals, INC | $21.14 | 2024 | Spravato |
| Alkermes, INC. | $15.65 | 2023 | Aristada, Lybalvi |
| Otsuka America Pharmaceutical, INC. | $13.72 | 2023 | Abilify Asimtufii |
| Takeda Pharmaceuticals U.S.A., INC. | $13.25 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Olayinka Toby listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.